$14,775 a Person: What US Health Spending Buys

The US Spends 17.2% of GDP on Health

Highest in the world

17.2%

**The US spends a larger share of its economy on health than any other country, and about $5,000 more per person than the next highest.**

Health Spending as a Share of GDP

• Highest in Europe12.3 %Germany’s social insurance system is among the most comprehensive in the world, funded through statutory contributions.
• Above peer average11.5 %France combines statutory health insurance with supplementary coverage, producing broad access at a high but not exceptional cost.
• Above peer average11.4 %The UK funds health primarily through general taxation via the NHS, at a share of GDP close to the European norm.
• The comparison group11.2 %Average across eleven comparable high-income countries — around $7,860 per person, roughly half the US figure.
• Below peer average10.6 %Japan spends less than the peer average despite having one of the world’s oldest populations.
• Across all members9.3 %The average across all OECD countries in 2024, including lower-income members outside the peer comparison group.

Overview

**In 2024 the United States spent $14,775 per person on health — approximately 17.2% of its entire economy. The average across eleven comparable high-income countries was $7,860, or 11.2% of GDP.**

The next highest peer spender, Switzerland, was almost $5,000 per person below the US figure. That is not a narrow lead; the gap between first and second place is larger than the total per-person health spending of many wealthy nations.

Set against that, US life expectancy in 2024 reached a record high of 79.0 years. The peer country average was 82.7 — a gap of 3.7 years, narrowed from 4.1 the year before.

Those two facts together are the reason health spending comparisons attract so much attention. This piece sets out what the figures actually measure, what can reasonably be concluded from them, and what cannot.

What These Numbers Actually Measure

Health spending comparisons are unusually easy to misread, so it is worth establishing the definitions before drawing conclusions from them.

Two measures appear throughout. Spending per capita divides total national health expenditure by population and is adjusted for purchasing power parity, which accounts for the fact that a dollar buys different amounts in different countries. Spending as a share of GDP expresses health expenditure as a proportion of the whole economy.

These measure genuinely different things. A wealthy country can spend a large absolute amount while devoting a modest share of its economy to health; a poorer country can devote a high share while spending little per person.

Both figures here cover total health expenditure — public and private combined. That distinction matters most for the United States, where a substantial portion of spending flows through private insurance rather than government programmes, and where comparisons using public spending alone give a very different picture.

The United States at 17.2% of GDP

The US devotes roughly one dollar in six of its entire economic output to health care. No other country approaches this.

**For scale, the OECD average in 2024 was 9.3% of GDP, and the average across the eleven comparable high-income countries was 11.2%. The US figure is close to double the OECD average.**

A share of GDP that large has consequences beyond the health system, because the money is not available for other purposes. Health spending competes with everything else an economy funds, and at 17.2% the competition is substantial.

**US per capita spending rose 6.4% in 2024. Notably, that increase was smaller than the rises in several peer countries — the Netherlands at 10.8%, Germany at 10.1%, Austria at 9.1% and Belgium at 8.0% — so on growth rates the US was not the fastest riser that year, even while remaining far ahead in level.**

$14,775 Against a Peer Average of $7,860

**The per capita figures make the gap more concrete than percentages do. The US spent $14,775 per person in 2024. The peer country average was $7,860 — the US spends approximately 88% more per person than comparable nations.**

**The eleven comparison countries are Australia, Austria, Belgium, Canada, France, Germany, Japan, the Netherlands, Sweden, Switzerland and the United Kingdom. These are wealthy nations with developed health systems and comparable disease burdens, which makes the comparison a reasonable one.**

**Switzerland, the highest-spending peer, was almost $5,000 per person below the US. The distance between the US and second place is therefore larger than the distance between second place and much of the rest of the group.**

Spending nearly twice as much as comparable countries is not in itself a criticism. The question it raises is what the additional expenditure produces, and that is where the data becomes harder for the current arrangement.

The Outcome That Complicates It

**US life expectancy reached 79.0 years in 2024 — a record high, and genuine progress worth acknowledging.**

**The comparable country average was 82.7 years. The US therefore trails peers by 3.7 years while spending roughly twice as much per person on health.**

Life expectancy is the most commonly cited outcome measure because it is consistently recorded across countries and is difficult to define away. It is also blunt, capturing everything that affects mortality rather than health system performance alone.

**There is also a notable internal divergence: the gap between women’s and men’s life expectancy is 4.9 years in the US, against 4.2 years across peer countries. The US disadvantage is not evenly distributed within its own population.**

Why the Gap Narrowed in 2024

**The life expectancy gap fell from 4.1 years in 2023 to 3.7 in 2024, and the reasons are specific rather than general.**

Age-adjusted mortality declined in the US across three areas: COVID-19, drug overdoses, and some chronic diseases. Each of these had been elevated in a way that depressed US life expectancy relative to peers.

**The COVID-19 component is partly a normalisation. The US experienced a heavy pandemic mortality burden, and its recession from that peak improves the comparison without indicating a structural change.**

**The decline in overdose mortality is the more consequential development, because overdose deaths concentrated among younger adults reduce average life expectancy disproportionately — a death at 35 removes far more years from the average than a death at 80. Whether the improvement persists is not something a single year of data can establish.**

Spending Is Not the Same as Health

The temptation with these figures is to conclude that the US health system is simply worse. The data supports a narrower claim than that, and the distinction is worth preserving.

Life expectancy is shaped substantially by factors outside medical care: diet, physical activity, road safety, firearm deaths, drug policy, income inequality and environmental conditions all contribute. A health system treats the results of these; it does not determine most of them.

**US clinical outcomes in specific areas — several cancer survival rates, for example, and outcomes following certain acute interventions — compare favourably with peer countries. The system performs well at treating serious illness once it presents.**

The defensible conclusion is therefore about efficiency of conversion rather than quality of care: the US converts health expenditure into population-level longevity less effectively than comparable countries do. That is a real finding, and it is not the same as saying the care itself is inferior.

Where the Additional Money Goes

If the extra spending is not producing proportionate gains in life expectancy, the question is what it is buying. Research on this points consistently in two directions.

The first is prices. The US pays substantially more for the same medical goods and services — pharmaceuticals, procedures, imaging, clinician compensation — than peer countries do. Where other systems set prices centrally or negotiate as a single purchaser, the US market is fragmented, and fragmented purchasing produces weaker pricing power.

The second is administration. A system with many insurers, benefit designs, provider networks and billing rules requires substantial administrative work on both the payer and provider side. That cost is real, it is counted in health expenditure, and it does not directly produce health.

Both explanations point at the same underlying feature: the US spends more per unit of care rather than delivering markedly more care. Utilisation rates in the US are broadly comparable to peer countries across many categories.

Germany, France and the United Kingdom

**The European comparators cluster together closely, which is itself informative given how differently their systems are organised.**

**Germany spends 12.3% of GDP, the highest in the peer group after the US. Its statutory social insurance model is comprehensive, and its per capita spending grew 10.1% in 2024 — faster than the US rate that year.**

**France is at 11.5% of GDP, combining statutory insurance with widespread supplementary cover. The United Kingdom is at 11.4%, funding health primarily through general taxation via the NHS.**

The clustering is the point worth drawing out. Social insurance in Germany, mixed insurance in France and tax-funded provision in the UK arrive within about a percentage point of one another. Very different funding structures produce similar total costs, which suggests the funding mechanism alone does not determine spending levels.

Japan Spends Less With an Older Population

**Japan is the most instructive case in the comparison group, spending 10.6% of GDP — below the peer average of 11.2%.**

This runs against the most reliable predictor of health spending. Japan has one of the world’s oldest populations, and older populations consume considerably more health care. On demographics alone Japan should be among the highest spenders.

Japan also achieves among the highest life expectancies recorded anywhere. It spends less than the peer average, considerably less than the US, and its population lives longer than either.

The explanation involves several factors that resist easy transfer: nationally negotiated fee schedules that constrain prices directly, high utilisation of relatively low-cost services, and dietary and lifestyle patterns that reduce disease burden before the health system is involved. Japan’s result is not purely a health system achievement, which is precisely why it is difficult for other countries to replicate.

How to Read These Comparisons

Several caveats apply to every figure in this article, and they are worth stating so the numbers are used carefully.

Purchasing power adjustments are estimates. Converting spending into comparable units requires assumptions about relative prices, and reasonable methods produce somewhat different results — small differences between similar countries should not be over-interpreted.

The public-private mix varies enormously and is invisible in totals. Two countries at 11% of GDP may distribute costs between government, employers and households in entirely different ways, with very different consequences for individual households.

**Reference groups matter too. The OECD average of 9.3% includes members considerably poorer than the peer comparison group, which is why it sits well below the peer average of 11.2%. Comparisons against these two benchmarks are not interchangeable, and the choice of comparison group changes the apparent size of any gap.**

Conclusion

**The United States spent $14,775 per person on health in 2024, about 17.2% of GDP, against a peer country average of $7,860 and 11.2%. The gap between the US and Switzerland, the next highest spender, is close to $5,000 per person.**

US life expectancy reached a record 79.0 years, while the peer average stood at 82.7 — a difference of 3.7 years, down from 4.1 in 2023 as COVID-19, overdose and some chronic disease mortality declined.

The evidence points toward prices and administrative complexity rather than volume of care as the main drivers of the difference. The US pays more per unit for broadly comparable levels of utilisation, and much of the additional expenditure does not translate into population-level longevity.

Japan is the sharpest counterpoint: 10.6% of GDP, below the peer average, with one of the world’s oldest populations and among the highest life expectancies recorded. What the comparison establishes is not that any one system is best, but that spending level and health outcome are far more loosely connected than the figures alone would suggest.